NewLimit

NewLimit bills itself as an ambitious new company focused on radically extending human healthspan using epigenetic reprogramming therapies. The company intends to develop intermediary products first, with the first two indications hypothesized to be ocular disease and immunosenescence. It has $105M in committed funding from the founders for the first two or three years of operations, with more capital available upon reasonable progress.

The company will focus on products over papers, use clear and apolitical communication, focus on safety then speed, and engage in optimism and independent thinking.